211 related articles for article (PubMed ID: 30556652)
1. 4"-O-Alkylated α-Galactosylceramide Analogues as iNKT-Cell Antigens: Synthetic, Biological, and Structural Studies.
Janssens J; Bitra A; Wang J; Decruy T; Venken K; van der Eycken J; Elewaut D; Zajonc DM; van Calenbergh S
ChemMedChem; 2019 Jan; 14(1):147-168. PubMed ID: 30556652
[TBL] [Abstract][Full Text] [Related]
2. Tailored design of NKT-stimulatory glycolipids for polarization of immune responses.
Hung JT; Huang JR; Yu AL
J Biomed Sci; 2017 Mar; 24(1):22. PubMed ID: 28335781
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and biological activities of amino acids functionalized α-GalCer analogues.
Ma W; Bi J; Zhao C; Zhang Z; Liu T; Zhang G
Bioorg Med Chem; 2020 Jan; 28(1):115141. PubMed ID: 31786009
[TBL] [Abstract][Full Text] [Related]
4. Synthesis of C-5″ and C-6″-modified α-GalCer analogues as iNKT-cell agonists.
Guillaume J; Pauwels N; Aspeslagh S; Zajonc DM; Elewaut D; Van Calenbergh S
Bioorg Med Chem; 2015 Jul; 23(13):3175-82. PubMed ID: 26003341
[TBL] [Abstract][Full Text] [Related]
5. Novel thioglycoside analogs of α-galactosylceramide stimulate cytotoxicity and preferential Th1 cytokine production by human invariant natural killer T cells.
Melo AM; Zhang L; Dockry ÉF; Petrasca A; Ghnewa YG; Breen EP; Morrissey ME; O'Reilly C; Bruen R; O'Meara A; Lysaght J; Zhu X; Doherty DG
Glycobiology; 2018 Jul; 28(7):512-521. PubMed ID: 29688330
[TBL] [Abstract][Full Text] [Related]
6. Structure-Function Implications of the Ability of Monoclonal Antibodies Against α-Galactosylceramide-CD1d Complex to Recognize β-Mannosylceramide Presentation by CD1d.
Clark K; Yau J; Bloom A; Wang J; Venzon DJ; Suzuki M; Pasquet L; Compton BJ; Cardell SL; Porcelli SA; Painter GF; Zajonc DM; Berzofsky JA; Terabe M
Front Immunol; 2019; 10():2355. PubMed ID: 31649670
[TBL] [Abstract][Full Text] [Related]
7. Activation of human invariant natural killer T cells with a thioglycoside analogue of α-galactosylceramide.
Hogan AE; O'Reilly V; Dunne MR; Dere RT; Zeng SG; O'Brien C; Amu S; Fallon PG; Exley MA; O'Farrelly C; Zhu X; Doherty DG
Clin Immunol; 2011 Aug; 140(2):196-207. PubMed ID: 21493160
[TBL] [Abstract][Full Text] [Related]
8. Invariant natural killer T cells: innate-like T cells with potent immunomodulatory activities.
Wu L; Gabriel CL; Parekh VV; Van Kaer L
Tissue Antigens; 2009 Jun; 73(6):535-45. PubMed ID: 19392798
[TBL] [Abstract][Full Text] [Related]
9. Avidity of CD1d-ligand-receptor ternary complex contributes to T-helper 1 (Th1) polarization and anticancer efficacy.
Wu TN; Lin KH; Chang YJ; Huang JR; Cheng JY; Yu AL; Wong CH
Proc Natl Acad Sci U S A; 2011 Oct; 108(42):17275-80. PubMed ID: 21987790
[TBL] [Abstract][Full Text] [Related]
10. Amide analogues of CD1d agonists modulate iNKT-cell-mediated cytokine production.
Wojno J; Jukes JP; Ghadbane H; Shepherd D; Besra GS; Cerundolo V; Cox LR
ACS Chem Biol; 2012 May; 7(5):847-55. PubMed ID: 22324848
[TBL] [Abstract][Full Text] [Related]
11. 3-fluoro- and 3,3-difluoro-3,4-dideoxy-KRN7000 analogues as new potent immunostimulator agents: total synthesis and biological evaluation in human invariant natural killer T cells and mice.
Hunault J; Diswall M; Frison JC; Blot V; Rocher J; Marionneau-Lambot S; Oullier T; Douillard JY; Guillarme S; Saluzzo C; Dujardin G; Jacquemin D; Graton J; Le Questel JY; Evain M; Lebreton J; Dubreuil D; Le Pendu J; Pipelier M
J Med Chem; 2012 Feb; 55(3):1227-41. PubMed ID: 22243602
[TBL] [Abstract][Full Text] [Related]
12. Negative modulation of invariant natural killer T cell responses to glycolipid antigens by p38 MAP kinase.
Stuart JK; Bisch SP; Leon-Ponte M; Hayatsu J; Mazzuca DM; Maleki Vareki S; Haeryfar SM
Int Immunopharmacol; 2010 Sep; 10(9):1068-76. PubMed ID: 20584631
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and evaluation of acyl-chain- and galactose-6''-modified analogues of α-GalCer for NKT cell activation.
Hsieh MH; Hung JT; Liw YW; Lu YJ; Wong CH; Yu AL; Liang PH
Chembiochem; 2012 Jul; 13(11):1689-97. PubMed ID: 22730199
[TBL] [Abstract][Full Text] [Related]
14. An in silico approach for modelling T-helper polarizing iNKT cell agonists.
De Spiegeleer A; Wynendaele E; Vandekerckhove M; Stalmans S; Boucart M; Van Den Noortgate N; Venken K; Van Calenbergh S; Aspeslagh S; Elewaut D
PLoS One; 2014; 9(1):e87000. PubMed ID: 24498010
[TBL] [Abstract][Full Text] [Related]
15. Immunomodulatory Functions of α-GalCer and a Derivative, α-Carba-GalCer.
Satoh M; Iwabuchi K
Methods Mol Biol; 2023; 2613():1-11. PubMed ID: 36587066
[TBL] [Abstract][Full Text] [Related]
16. The Vα14 invariant natural killer T cell TCR forces microbial glycolipids and CD1d into a conserved binding mode.
Li Y; Girardi E; Wang J; Yu ED; Painter GF; Kronenberg M; Zajonc DM
J Exp Med; 2010 Oct; 207(11):2383-93. PubMed ID: 20921281
[TBL] [Abstract][Full Text] [Related]
17. Synthesis of C6''-modified α-C-GalCer analogues as mouse and human iNKT cell agonists.
Guillaume J; Seki T; Decruy T; Venken K; Elewaut D; Tsuji M; Van Calenbergh S
Org Biomol Chem; 2017 Mar; 15(10):2217-2225. PubMed ID: 28221388
[TBL] [Abstract][Full Text] [Related]
18. Galactosylsphingamides: new α-GalCer analogues to probe the F'-pocket of CD1d.
Guillaume J; Wang J; Janssens J; Remesh SG; Risseeuw MDP; Decruy T; Froeyen M; Elewaut D; Zajonc DM; Calenbergh SV
Sci Rep; 2017 Jun; 7(1):4276. PubMed ID: 28655912
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and functional activity of labeled CD1d glycolipid agonists.
Jervis PJ; Polzella P; Wojno J; Jukes JP; Ghadbane H; Garcia Diaz YR; Besra GS; Cerundolo V; Cox LR
Bioconjug Chem; 2013 Apr; 24(4):586-94. PubMed ID: 23458425
[TBL] [Abstract][Full Text] [Related]
20. Species-specific activity of glycolipid ligands for invariant NKT cells.
Dangerfield EM; Cheng JM; Knight DA; Weinkove R; Dunbar PR; Hermans IF; Timmer MS; Stocker BL
Chembiochem; 2012 Jun; 13(9):1349-56. PubMed ID: 22639457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
